{"schema_version":"1.0","type":"article","title":"打一針，身體自己造抗癌細胞？","url":"https://drugnews.com.tw/articles/2026-10-07-in-vivo-car-t-iaso206-first-human.html","markdown_url":"https://drugnews.com.tw/articles/2026-10-07-in-vivo-car-t-iaso206-first-human.md","lang":"zh-Hant","date":"2026-10-07","publish_at":"2026-10-07T08:00:00+08:00","updated_at":"2026-10-07","category":"商業分析系列","topic":"商業分析系列","tags":["CAR-T","體內CAR-T","IASO206","BCMA","細胞治療"],"summary":"對準備接受傳統自體CAR-T治療的人，醫師說「可以試這個療法」，並不代表明天就有藥。","key_points":[],"facts":[],"sections":[],"references":[],"images":[{"alt":"傳統自體與體內CAR-T兩條流程；先在體外製造細胞，或先製造遞送載體再於體內改造T細胞。","url":"https://drugnews.com.tw/assets/articles/in-vivo-car-t-iaso206-first-human/FIG01_ZH_R1.png"},{"alt":"載體遞送到T細胞、T細胞特異啟動子控制指令表現、CAR受體辨認另一個骨髓瘤細胞上的BCMA。","url":"https://drugnews.com.tw/assets/articles/in-vivo-car-t-iaso206-first-human/FIG02_ZH_R1.png"},{"alt":"十位患者中九位客觀反應；無體外細胞製造與清淋，病毒感染兩人為另列安全觀測，並非互斥分組。","url":"https://drugnews.com.tw/assets/articles/in-vivo-car-t-iaso206-first-human/FIG03_ZH_R1.png"},{"alt":"工廠供應、醫院安全承接與患者效果三個問題，付款涵蓋給藥、監測、感染處置及追蹤。","url":"https://drugnews.com.tw/assets/articles/in-vivo-car-t-iaso206-first-human/FIG04_ZH_R1.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/in-vivo-car-t-iaso206-first-human/FIG01_ZH_R1.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-10-07）。打一針，身體自己造抗癌細胞？。https://drugnews.com.tw/articles/2026-10-07-in-vivo-car-t-iaso206-first-human.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-10-07-in-vivo-car-t-iaso206-first-human-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}